1. Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

2. Baseline characteristics of new users of statins and non-users of statins aged 30-84 years in the QResearch derivation and THIN validation cohorts Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

3. Adjusted HRs (95% CI) for moderate to severe myopathy Models also adjusted for age and body mass index Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

4. Validation statistics for each model in the THIN and QResearch validation cohorts Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

5. Adjusted HRs (95% CI) for acute renal failure Models also adjusted for age and body mass index Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

6. Adjusted HR (95% CI) for moderate/serious liver dysfunction Models also adjusted for age and body mass index Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

7. Adjusted HR (95% CI) for cataract Models also adjusted for age and body mass index Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

8. Predicted to observed risk of each outcome using the QResearch database Hippisley-Cox J, Coupland C. Heart 2010;96:939-47

9. Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases, for each outcome over 5 years in patients aged 35-74 free of cardiovascular disease at baseline with QRISK2 score of 20%+ Hippisley-Cox J, Coupland C. Heart 2010;96:939-47